Publications

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS I.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS II.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS IVA.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for MPS VI.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D).

Treating Physicians use this application form to apply for a patient to access LSDP medication for Infantile-onset lysosomal acid-lipase deficiency disease (LAL-D) for the first time, or after a break.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for infantile onset lysosomal acid lipase deficiency (LAL-D) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access asfotase alfa (Strensiq®) for perinatal- and infantile-onset hypophosphatasia under the Life Saving Drugs Program.

Treating physicians use this application form to apply for a patient to access LSDP medication for HPP for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for HPP.

Specialists use this spreadsheet to report their patient's test results when reapplying for treatment under the Life Saving Drugs Program.

This poster outlines the COVID-19 vaccine doses recommended for each age and population group.

This manual will help Aged care providers submit a specialisation application and to learn how the Specialisation Verification assessment process works.

This fact sheet provides advice to health professionals on the changes to Meningococcal ACWY vaccines under the National Immunisation Program (NIP).

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

This fortnightly Australian Respiratory Surveillance Report (ARSR) includes information about acute respiratory illnesses including COVID-19, influenza and respiratory syncytial virus.

The Statement of Expectations sets out the role for the Aged Care Quality and Safety Commission in preparing the sector for the new Aged Care Act.

This document outlines the updates to the LSDP’s testing requirements for Pompe disease, Gaucher disease (type 1), and mucopolysaccharidosis types I, II, and VI arising from the LSDP Expert Panel’s Medicines Reviews Recommendations.

This fact sheet supports care recipients to understand their monthly statement and the responsible use of Home Care Package funds. It accompanies the Care Recipient Guidance – Understanding your Home Care Package statement.

These are the presentation slides for the Residential aged care funding reform update webinar held on September 18 2024.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1).